The civil money complaints, which carry a maximum penalty of $19,192 for a single violation, are intended to hold tobacco companies accountable for selling e-liquids—or vape juice—without FDA approval.
The FDA said Wednesday that for the first time, it has filed civil money penalty (CMP) complaints against 4 tobacco product manufacturers for manufacturing and selling e-liquids without marketing authorization.
The CMP complaints, which carry a maximum penalty of $19,192 for a single violation, are aimed at enforcing the federal Food, Drug, and Cosmetic (FD&C) Act’s premarket review requirements for new tobacco products. The FDA said it is seeking the statutory maximum allowed by law.
The FDA said it previously warned each of the companies that, by making and selling their products without marketing authorization, they were in violation of premarket requirements for tobacco products and that failure to correct the violations could lead to an enforcement action. It is illegal to manufacture, sell, or distribute e-liquids that the FDA has not authorized.
The companies continue to make and sell their unauthorized e-liquids despite the agency’s warnings, the FDA said.
“Holding manufacturers accountable for making or selling illegal tobacco products is a top priority for the FDA,” Brian King, PhD, MPH, director of the FDA’s Center for Tobacco Products, said in a statement. “We are prepared to use the full scope of our authorities to enforce the law—especially against those who have continued to violate the law after being warned by the agency.”
The 4 firms are:
The companies may pay the penalty, enter into a settlement agreement, request an extension of time to file an answer to the complaint, or file an answer and request a hearing.
Companies that do not take action within 30 days after receiving the complaint risk a default order imposing the full penalty amount.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
2 Commerce Drive
Cranbury, NJ 08512